{"entity":{"id":"src","kind":"target","name":"SRC family kinases","aka":[],"tldr":"The first cancer gene ever identified, a kinase that relays growth, adhesion and movement signals. Dasatinib and bosutinib were designed as BCR::ABL1 drugs but also hit SRC-family kinases, part of the reason they work when imatinib has failed.","summary":"SRC, discovered through the Rous sarcoma virus, heads a family of non-receptor tyrosine kinases (SRC, LYN, LCK, HCK, FYN, YES1) that sit downstream of growth-factor receptors and integrins. Dasatinib and bosutinib inhibit both BCR::ABL1 and SRC-family kinases and are approved for chronic myeloid leukaemia and, for dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia; LYN signalling contributes to imatinib resistance, so the dual activity matters. Selective SRC inhibitors have not succeeded in solid tumours despite frequent SRC activation, a reminder that activation and dependency are not the same thing.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Proto-oncogene_tyrosine-protein_kinase_Src","links":[{"label":"UniProt P12931: SRC","url":"https://www.uniprot.org/uniprotkb/P12931/entry"}],"tags":[],"related":[],"cancers":["cml","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["dasatinib","bosutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"SRC","role":[],"sources":[],"specificity":"broadly-expressed","distribution":"one-type","specificityNote":"Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 2 medicines aimed at it (Dasatinib, Bosutinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA SRC: RNA low tissue specificity; blood lineage group enriched (dendritic cells 1 nTPM, monocytes 2 nTPM); high antibody staining in 10 normal tissues; highest cancer staining skin cancer (5 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Leukaemia); Open Targets associates it with 4 specific cancer types at or above 0.5 (chronic myeloid leukemia, actinic keratosis, acute lymphoblastic leukemia, medullary thyroid gland carcinoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas SRC tissue","url":"https://www.proteinatlas.org/ENSG00000197122-SRC/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000197122 associations","url":"https://platform.opentargets.org/target/ENSG00000197122/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:11283","ensembl":"ENSG00000197122","uniprot":"P12931","entrez":"6714","firstDescribed":1985,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Anderson S.K. et al, Mol. Cell. Biol, 1985, \"Human cellular src gene: nucleotide sequence and derived amino acid sequence of the region coding for the carboxy-terminal two-thirds of pp60c-src\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2582238/","biology":"Non-receptor tyrosine kinase family downstream of receptor tyrosine kinases and integrins; dual BCR::ABL1 and SRC-family inhibition by dasatinib and bosutinib.","whereFound":["Chronic myeloid leukaemia and Ph-positive ALL (as a secondary target)","Activated in many solid tumours without proven dependency"],"targetClass":"kinase","prevalence":[{"cancerId":"metastatic-cancer","pct":"all","measure":"Signalling protein present in most cells (SRC family kinases); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies."}]},"route":"/targets/src/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/"},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/"}],"trial":[{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/"}],"target":[{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/"},{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/"},{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/"},{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/"}]}}